Boston Scientific won FDA approval to introduce its Resonate line of implantable cardioverter defibrillators (ICD) and cardiac resynchronization therapy defibrillators (CRT-D). The same products were approved in Europe via a CE Mark earlier this year.
Some of the notable features of the Resonate devices include multi-electrode pacing and integration with the company’s HeartLogic Heart Failure Diagnostic Service, essentially an algorithm that seems to do a good job predicting heart failure events.
The internal battery technology allows Boston Scientific to claim the battery capacity of the Resonate ICD devices being substantially more than that of Medtronic’s Evera XT VR, though the actual working life can’t be compared directly for a number of reasons.
More from Boston Scientific’s announcement:
The company has initiated a series of clinical trials, the SMART Registry, SMART CRT Study and SMART MSP, to demonstrate improved response to CRT therapy with SmartCRT technology, which helps physicians optimize where, when, and how to pace the lower chambers of the heart.
“These trials will add to the body of evidence showing CRT therapy can be tailored to individual patient characteristics at the time of implant, while adjusting device programming solutions over the life of the device without fear of adversely draining the device battery and causing unnecessary replacement procedures,” said Dr. Michael Gold, principal investigator of the SMART CRT study and the Michael E. Assey professor of medicine at The Medical University of South Carolina, Charleston.
Product page: RESONATE…
Via: Boston Scientific…